Pharma BD Deal Intelligence

AbbVie Inc. / Infinity Pharmaceuticals, Inc.

2014 · Co-Development · $805M · Terminated

AbbVie paid Infinity $275M upfront plus up to $530M in development and regulatory milestones plus tiered royalties for global rights to duvelisib, a dual PI3K-delta/gamma inhibitor in late-stage development for hematologic cancers. AbbVie returned rights in 2016; duvelisib (Copiktra) eventually commercialized by Verastem.

Key facts

• Announced Sep 04, 2014
• Closed Sep 04, 2014
• Deal value $805M
• Deal type Co-Development
• Therapeutic area Hematologic malignancies including CLL, iNHL, peripheral T-cell lymphoma
• Indications Hematologic malignancies including CLL, iNHL, peripheral T-cell lymphoma
• Key assets Duvelisib (IPI-145)
• Mechanism Oral dual PI3K-delta/gamma inhibitor

← Browse all deals  ·  How we score deals